Search SciPol

Brought to you by
May 4, 2017 1:00 pm - May 4, 2017 5:00 pm

Meeting: FDA Patient-Focused Drug Development for Autism

  • Agency
  • Neuroscience

The Food and Drug Administration (FDA) is announcing a public meeting and an opportunity for public comment on Patient-Focused Drug Development for autism. Patient-Focused Drug Development is part of FDA's performance commitments made as part of the fifth authorization of the Prescription Drug User Fee Act (PDUFA V). The public meeting is intended to allow FDA to obtain patient perspectives on the impact of autism on daily life as well as patient views on treatment approaches for autism.

More information is available via the Federal Register notice.